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INTRODUCTION 
DISEASES OF THE PROSTATE ACCOUNT FOR CONSIDERABLE 
MORBIDITY AND MORTALITY AMONG AGING POPULATION 
WORLDWIDE.Patients presenting with prostatic symptoms account for 22% of 
the total urology cases,and every 7 th patient will be presenting with urologic 
emergency.(12,59) 
PROSTATITIS, BENIGN NODULAR HYPERPLASIA AND 
PROSTATIC ADENOCARCINOMA ARE COMMON DISEASES 
AFFECTING MEN COMMONLY AFTER THEIR FIFTH DECADE.(8,28,49) 
There has been steadily increasing interest in prostatic pathology as reflected 
by numerous publications in the last decade.(28) 
The clinical and basic scientific studies have led to a better understanding of 
previously recognized tumours and morphologic studies have described many new 
entities.(28,49) 
The histopathologic spectrum of prostatic hyperplasia has been broadened 
with descriptions of several variants and work done primarily in the last two 
decades has considerably expanded our knowledge of the pathology and 
BIOLOGY OF PROSTATIC ADENOCARCINOMA,IN PARTICULAR ITS 
POSSIBLE PRECURSOR LESIONS,SPECIAL HISTOLOGIC VARIANTS 
AND PROGNOSTIC FACTORS.(25,37,44) 
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The CLINICAL INCIDENCE of nodular hyperplasia is only 8% during 4 
th decade,but it REACHES 50% IN THE 5 TH DECADE AND 75% IN THE 8 
TH DECADE.It has been estimated that the process begins before the age of 30 
and that its doubling time progressively increases from the early to late 
stages.(37,44,53,55) 
PROSTATIC CARCINOMA IS THE LEADING CAUSE OF NEWLY 
DIAGNOSED CANCER IN WESTERN MEN and second only to lung cancer 
as a leading cause of cancer related deaths in men.(28) 
THE AGE ADJUSTED INCIDENCE IS ON THE RISE IN MOST 
COUNTRIES INCLUDING INDIA.(28,55,41) 
Almost 75% of the men diagnosed with PROSTATIC CARCINOMA are 
aged 65 OR OLDER,but the tumours can be seen even in children and adolescents 
though,very rarely.(11,12,21,28) 
Normal and benign glands may contain neutral mucosubstances whereas 
invasive carcinomas and precursor lesions may harbour acid mucins.Thus mucin 
histochemistry may be used as an ancillary method for diagnosing diseases of 
prostate.(16,20,24,36) 
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THE NUMBER OF MITOTIC FIGURES INCREASED 
PROGRESSIVELY FROM BENIGN EPITHELIUM THROUGH 
PRECURSOR LESION TO MALIGNANCY.HENCE,ELEVATION IN THE 
PROLIFERATION INDICES OF KI – 67 APPEARS TO REFLECT 
PROGRESSION AND IS BECOMING AN IMPORTANT DIAGNOSTIC 
AND PROGNOSTIC FACTOR.(4,12,13,32,33,45,49,53,55,59) 
This study is undertaken in view of evaluating the actual incidence of 
different prostatic lesions in semi urban area like Thanjavur with particular 
attention to proliferative status of precancerous and different grades of frankly 
malignant lesions.In addition, the recent literatures,journals and research 
publications regarding prostatic pathology are also immensely reviewed. 
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AIM OF THE STUDY 
 
1) To analyse the incidence of various prostatic lesions in our institution 
during 2006-2008. 
2) To sub classify the lesions and their prevalence. 
3) To SUBTYPE THE NEOPLASTIC LESIONS. 
4) To exactly DIFFERENTIATE THE PROSTATIC CARCINOMA 
MIMICKERS   FROM   WELL   DIFFERENTIATED 
CARCINOMAS. 
5) To APPLY UPGRADED GLEASON’S TERTIARY GRADING 
SYSTEM FOR PROSTATIC CARCINOMA. 
6) To study THE NATURE OF MUCIN EXPRESSION IN 
VARIOUS PROSTATIC LESIONS. 
7) To study and COMPARE THE PROLIFERATIVE ACTIVITY 
WITH IMMUNOHISTOCHEMICAL MARKER KI-67 IN 
BENIGN, PRECURSOR AND INVASIVE LESIONS OF 
PROSTATE. 
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MATERIALS AND METHODS 
This prospective study includes 120 cases of prostatic lesions,referred from 
UROLOGY DEPARTMENT OF THANJAVUR MEDICAL 
COLLEGE,THANJAVUR,DURING THE TWO YEAR PERIOD FROM 
JUNE 2006 TO MAY 2008. 
 A detailed clinical history  like age,duration of complaints,nature of 
symptoms and haematological investigations were done in all cases. 
 All specimen we received were TURP specimen.Every tissue was carefully 
examined for the presence of yellow and/or hard areas and necrotic areas.As per 
the literature if all fragments received in a single container,all of the specimen 
submitted until four cassettes filled and if in excess,one additional cassette for each 
additional 10 gram of tissue. 
 In our cases,all specimen ranged in volume from 1 to 10 grams.Fixation was 
done by neutral buffered 10% formalin and the fixation period was 12 hrs.After 
adequate fixation,the entire specimen was submitted for processing. 
 Tissue processing was done with automated tissue processor and sections 
were made manually with histokinette of thickness 2 to 4 microns.Staining was 
done with routine haematoxylin and eosin and every slide was examined 
thoroughly and looked for the presence of malignancy,prostatic Intraepithelial 
Neoplasms,Atypical Adenomatous Hyperplasia,metaplasia,acute and chronic 
inflammation and other secondary changes associated with benign nodular 
hyperplasia. 
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 To study the mucin histochemistry in benign,precursor and invasive 
lesions,Alcian blue at pH 2.5 and PAS were used.ALCIAN BLUE was the best 
available routine method to demonstrate acidic,weakly sulphated or acid-non 
sulphated mucosubstances when used at pH 2.5. 
 With PAS, it was accepted that acidic mucosubstances usually give a 
negative result. 
IMMUNOHISTOCHEMISTRY WITH PROLIFERATIVE MARKER KI 67 
was done for 10 cases which included Nodular Hyperplasia,prostatic intraepithelial 
neoplasia,low and high grade carcinomas.Randomly 100 cells per samples were 
examined and the number of positive cells with nuclear staining were noted. KI – 
67 LABELLING INDEX ( KI – 67 LI ) expressed as percentage of KI – 67 
positive cells. 
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REVIEW OF LITERATURE 
Diseases of the prostate gland are common afflictions of men. In 
particular,prostatitis, Benign Nodular hyperplasia and prostate cancers are 
remarkably prevalent clinical disorders (32,48,53,55) 
The human prostate gland is one of the male accessory sex organ 
which include the prostate, seminal vesicle and bulbourethral glands (32, 49, 47) 
ANATOMY 
The prostate gland is situated in the true pelvis between the bladder 
neck and urogenital diaphragm. It lies behind the inferior aspect of the 
symphysis pubis and anterior to the rectum. The prostate gland in young 
adults weighs about 20g and measures 4X3X2 cms. While the weight of the 
prostate gland has traditionally been thought to be relatively constant 
between the ages of 20 and 50, more recent autopsy date suggest a stepwise 
increase in prostatic weight with each decade of life.(49,53) 
The prostate gland has an inverted conical shape with the base, the 
region of attachment of the seminal vesicles, in direct continuity with the 
bladder neck and the apex with the urogenital diaphragm. The prostate is 
organized around the first part of the urethra. Two ejaculatory ducts traverse 
the prostate. (32, 41, 47, 49) 
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ANATOMIC MODELS 
Since, the early part of this century several models have been 
proposed. The one proposed by Mc Neal have now largely replaced previous 
models. In Mc Neal model, the key reference point is the prostatic urethra 
which has a 35 degree angulation in the midportion creating proximal and 
distal segments of about equal length. The verumontanum is part of the point 
of the distal urethral segment and consists of a bulge at the point of 
angulation.Glandular zones are arranged in relation to the prostatic urethra 
and ejaculatory ducts (25, 41, 49) 
Mc Neal’s model divides the prostate in to the three zones, the 
transition zone, peripheral zone and central zone each of which has a 
different glandular organization and proclivity for disease (25, 41, 49, 59) 
FIGURE 1 
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¾ Transition zone - 5 % of volume, chief source of NH, 15-20% of  
carcinomas , 
¾ Central zone - 25% of volume, 10% carcinomas , 
¾ Peripheral zone -70% of Volume, 70-75% of Carcinomas(49) 
HISTOLOGY 
The prostate gland has a compound tubuloalveolar organization with 
some variation in histology in the three zones. The acinar units responsible 
for prostatic secretion open in to a series of ramifying ducts which empty in 
to large primary ducts, which open in to the prostatic urethra.(9,11,49 ) 
The prostatic acini and ducts, except for the immediate periurethral 
segment, are lined by a double-layered epithelium consisting of secretory 
and basal cells. The secretory cells are cuboidal to columnar. They generally 
have basally located, uniform nuclei and abundant apical cytoplasm which is 
pale and granular. These cells are responsible for the production and release 
of  biochemical products.The secretory cells rest on a basal cell layer which 
consists of cuboidal to flattened attenuated cells with relatively high nuclear 
to cytoplasmic ratios. The basal cells rest on a delicate basement membrane 
which is not usually visualized with routine stains. A population of stem 
cells resides within the basal cell compartment.    (41, 49, 59) 
 14
Prostatic secretion is commonly present at least focally, which is PAS 
positive. Neutral mucin may also be seen in prostatic adenocarcinoma. 
Acidic mucins are not usually found in normal or hyperplastic glands but are 
commonly found, at least focally, in prostatic adenocarcinoma (16, 49) 
Corpora amylacea are laminated luminal concretions that are commonly 
present in prostatic glands and increase in prevalence in prostate with 
advancing age (25) 
The prostatic ducts and acini are surrounded by stroma consisting of 
smooth muscle cells, fibroblasts and undifferentiated spindle cells embedded 
in a matrix consisting of collagen and ground substance.In addition, prostate 
gland also has neuroendocrine cells, lipofuscin and melanin pigments. (11, 32, 
48) 
With advancing age, the prostate gland is commonly involved by both 
atrophy and hyperplasia. 
HISTOCHEMICAL FEATURES 
Normal and hyperplastic prostate glands may contain neutral 
mucosubstances, both neutral and acid mucopolysaccharides are found 
predominantly in neoplastic disease including both prostatic intraepithelial 
neoplasia and adenocarcinoma. Mucin studies will confirm the mucinous 
nature of the often blue-tinged secretions frequently seen in neoplastic 
acini.Usually only small amount of mucin is identified within the lumens.(19, 
20, 23, 36) 
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Elbadawi et al reported that neutral mucins may be secreted in small 
amount by prostatic epithelial cells whether benign or malignant and they 
are present in cytoplasmic granules. They are variably eosinophilic and are 
stained by the PAS technique.(16, 20, 23, 36, 51) 
          
          Frank et al and hukill et al in their independent studies stated that acid 
mucins are rare and scant in benign prostate gland lumina and their abundant 
secretion is specific for mucinous areas of prostatic cancer. They are usually 
faintly basophilic with H&E stain, but they are specifically identified by 
Alcian blue technique which does not stain the neutral mucin .(20,23,36) 
        
          Morphological and histochemical analysis by Mc Neal revealed mucin 
secreting areas in 33% of prostatic adenocarcinoma.Taylor reported that the 
presence of acid mucin is of diagnostic significance.Ro et al agrees that the 
stains for acid mucopolysaccharides are useful in confirming the diagnosis 
of prostate cancers especially in equivocal cases .(16,20, 23). 
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IMMUNOHISTOCHEMICAL FEATURES 
The secretory cells and the basal cells stain with a variety of keratin 
antibodies. The basal cells in addition, demonstrate positivity with 
antibodies against high molecular weight keratin.The antibody designated 
34BE12 has specificity for high molecular weight cytokeratins and has been 
widely used to demonstrate basal cells, which is important diagnostically. 
The complete absence of basal cells in an acinar proliferation is an important 
criteria for malignancy and is useful in separating small acinar paterrns of 
carcinoma  from carcinoma mimickers such as atrophy, postatrophic 
hyperplasia, radiation induced atypia and atypical adenomatous 
hyperplasia.(11, 13, 19, 25,28) 
PROSTATE SPECIFIC ANTIGEN (PSA) & PROSTATIC ACID 
PHOSPHATASE      ( PAP) 
Glandular epithelia from all prostatic zones stain with PSA.. Most 
adenocarcinomas display positivity with PSA antibodies, although there is 
considerable irtertumoural and intratumoural variation in extent and 
intensity .(11, 13, 32, 41, 49). 
PAP is found in normal and hyperplastic and also in most prostatic 
adenocarcinomas. The histochemical assessment of PAP is limited because 
of its non specificity. Antibodies to PAP and PSA are useful in 
adenocarcinomas of unknown origin and in poorly differentiated carcinomas 
of the lower genitourinary tract where the differential diagnosis includes 
prostatic adenocarcinoma and urothelial carcinoma (11, 13, 25, 49) 
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WHO CLASSIFICATION OF PROSTATIC HYPERPLASIA, 
TUMOURS AND TUMOUR LIKE LESIONS 
Hyperplasia 
¾ Benign nodular hyperplasia 
¾ Basal cell hyperplasia 
¾ Post atrophic hyperplasia 
¾ Atypical adenomatous hyperplasia (adenosis) 
Benign epithelial tumors 
¾ Adenoma 
¾ Multilocular cystadenoma 
Prostatic intraepithelial neoplasia 
Conventional adenocarcinoma 
Special Variants of adenocarcinoma and other carcinomas 
¾ Prostatic duct adenocarcinoma 
¾ Mucinous (colloid) adenocarcinoma 
¾ Signet ring cell carcinoma 
¾ Adeno squamous carcinoma 
¾ Squamous cell carcinoma 
¾ Basaloid and adenoid cystic carcinoma 
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¾ Transitional cell carcinoma 
¾ Small cell carcinoma 
¾ Sarcomatoid carcinoma 
¾ Lymphoepithelioma-like carcinoma 
¾ Undifferntiated carcinoma, not otherwise specified. 
Mixed Tumours 
¾ Epithelial-stromal tumour ,not otherwise specified 
¾ carcinosarcoma. 
Mesenchymal tumours: 
¾ Benign  
¾ Leiomyorma 
¾ Fibroma 
¾ Hemangioma 
¾ Others 
Malignant 
¾ Rhabdomyosarcoma 
¾ Leiomyosarcoma 
¾ Stromal sarcoma 
¾ Others 
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Other tumours 
¾ Hematolymphoid neoplasms 
¾ Paraganglioma 
¾ Germ cell tumours 
¾ Willm’s tumour 
Secondary tumours 
Tumour-like lesions. 
BENIGN NODULAR HYPERPLASIA 
Benign nodular hyperplasia represents nodular expansion of prostatic 
glandular elements, stromal elements, or both.(32, 49)The prevalence of 
nodular hyperplasia in austopsy series increases with advancing age from 
about 8% in the fourth decade to almost 90% at 80 years.In a clinical series 
of 1000 cases of prostatic hyperplasia, the youngest patient was 40 years 
age, and 98% were over 50 years.(47, 53,55) 
The etiology and pathogenesis of nodular hyperplasia remain poorly 
understood. A number of factors, including marital status, socioeconomic 
status,  libido, and diseases such as diabetes mellitus, hypertension, and 
cirrhosis, have been investigated and are not thought to be etiologically 
related to nodular hyperplasia. Testicular androgen production is necessary 
for the development of nodular hyperplasia. (47, 59) 
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The principal androgenic hormones are testosterone and 
dihydrotestosterone(DHT). DHT is the active metabolite of testosterone 
which many believe is related to the development of nodular hyperplasia (47, 
59) 
Nodular hyperplasia preferentially involves the proximal periurethral 
tissues (the so called estrogen sensitive zone). The transition zone expands 
with advancing age, resulting in a nodular gross appearance due to the lobar 
architecture of this zone; most clinically significant nodules develop here. (25, 
32, 49) 
It is likely that the pathogenesis of nodular hyperplasia is 
multifactorial and  involves hormonal alterations,stromal-epithelial 
communication and fundamental changes in proliferative cellular 
compartments. (49,50) 
CLINICAL FEATURES 
About 50% of patients with grossly enlarged glands develop 
prostatism. The symptoms may be categorized as either obstructive or 
irritative. Obstructive symptoms include hesitancy, weak stream, and 
terminal dribbling. Irritative symptoms include pain,increased frequency and 
dysuria. 
 21
The severity of symptoms does not necessarily correlate with gland 
size. Patient may present with acute urinary retention resulting from 
complete blockage. This situation present a urologic emergency. (53,59, 65) On 
digital rectal examination, the prostatic gland in typically large and may 
have a nodular contour. The enlargement is often symmetric, and the texture 
is rubbery. Tenderness may be present, especially if there is superimposed 
prostatitis. (49) 
FRANK’S CLASSIFICATION OF HYPERPLASTIC NODULES. (49) 
¾ The stromal (fibrous or fibrovascular) nodule, 
¾ The fibromuscular nodule, 
¾ The muscular nodule, 
¾ The fibroadenomatous nodule, 
¾ The fibromyoadenomatous nodule. 
The glands of nodular hyperplaisa are usually medium to large, 
sometimes cystic and may show architectural complexity and papillary 
infoldings. The epithelium usually has distinct double layer of secretory and 
basal cells, but the basal cells are not always conspicuous. The cells are 
often thrown in to papillary folds with some stratification, although the 
nuclei are usually aligned in a single row. (49, 53, 55) 
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SPECIAL HISTOLOGIC PATTERNS: (49) 
1) Small glandular hyperplasia:. 
Circumscribed proliferation of relaively small uniform glands in a 
fibramuscular stroma. 
2) Cribriform hyperplasia: 
Epithelial component consists of medium to large glands with a 
cribriform architecture. The cells may have abundant clear cytoplasm 
(“clear cell cribriform hyperplasia”) 
3) Leiomyomatous nodules: 
Stromal nodules with prominent smooth muscle differentiation often 
cellular with mild  nuclear  variability. 
4) Fibroadenoma like hyperplasia: 
Glands and cellular fibrovascular stroma are organized in a fashion 
similar to fibroadenoma of breast. 
5) Phyllodes-type hyperplasia: 
In exuberant, sometimes myxoid, stromal proliferation, usually 
associated with intraluminal polypoid  projections like phyllodes 
tumour of the breast. 
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SECONDARY CHANGES AND OTHER ASSOCIATED FINDINGS: 
Sclerosing adenosis, cystic dilatations, corpora amylacea, 
psammomatous calcification, oncocytic or mucinous metaplasia, cystic 
dilatation, acute and chronic inflammation, basal cell hyperplasia, squamous 
metaplasia, transitional metaplasia, infarction are at times noted. PIN and 
atypical adenomatous hyperplasia may be seen in association with nodular 
hyperplasia. (37, 44, 53) 
BASAL CELL HYPERPLASIA: 
Typically found in the transition zone, but may also be atrophy 
associated and found in the peripheral zone. The nodule of nodular 
hyperplasia may be partially or completely involved. The basal cells are 
multi layered and relatively uniform, with a high nuclear to cytoplasmic 
ratio. When well delineated, the term basal cell adenoma has been used. (48, 
53, 55) 
Classification of prostatic basal cell hyperplasia: (49, 55, 47) 
¾ Complete 
¾ Incomplete 
¾ Atypical basal cell hyperplasia 
¾ Adenoid cystic-like basal cell hyperplasia 
¾ Atrophy associated basal cell hyperplasia 
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The differential diagnosis are transitional cell metaplasia, prostatic intra 
epithelial neoplasia, conventional adenocarcinoma and basaloid carcinom(47, 
49, 55) 
PROSTATIC INTRAEPITHELIAL NEOPLASIA(PIN) 
PIN is usually characterised by intraluminal proliferation of secretory 
epithelium that displays a spectrum of changes culminating in those that are 
indistinguishable from carcinoma. Occasionally, there is cytologic atypia 
without increased cellularity. High grade PIN(HGPIN) is strongly associated 
with invasive adenocarcinoma, particularly of the peripheral zone. (28, 45, 53) 
There is much evidence supporting a preneoplastic role of PIN. The 
prevalence of PIN increases with age, peaking in the 6th decade and 
predating the onset of most carcinomas by more than 5 years. PIN is much 
more common in prostates with carcinoma than in benign glands and is more 
often multifocal, more extensive and of higher grade in the former . Like 
carcinoma, PIN is mainly identified in the peripheral zone and is often 
adjacent to carcinoma. (28, 49, 59) 
The extent of PIN is inversely related to the tumour stage, this may be 
related to replacement of areas of PIN by invasive tumour. As in carcinoma, 
increased production of acid mucin has been demonstrated. 
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The cytologic appearance of the cells of high grade PIN are similar to 
those seen in invasive carcinoma.Increased numbers of mitoses and 
apoptotic bodies, compared to benign glands have been identified, although 
in general there is a paucity of mitotic figures  in PIN. (28, 49, 53,55) 
In high grade PIN there is a partial loss of the basal cell layer while in 
carcinoma there is a complete loss. On occassion, carcinoma may be seen 
arising directly form an area of high grade PIN, a phenomenon that led MC 
Neal to propose the concept of microinvasion in association with high-grade 
PIN. (49,59) 
There are no specific associated clinical features. Some patients 
present with elevated prostate-specific antigen levels, but this is likely often 
due to undetected invasive carcinoma. (59) 
Mc Neal and Bostwick initially proposed a three grade system based 
on progressive abnormalities in architecture and cytology .Later, it was 
agreed to divide the process in to two grades, low and high. PIN 1 is now 
considered low grade (LGPIN) and PIN 2 and 3, high grade(HGPIN). (4, 10, 
28, 49) 
LOW GRADE PIN (LGPIN): Glands with crowding, stratification, 
irregular spacing of secretory cells. The nuclei are enlarged and there is 
anisonucleosis with usually inconspicuous nucleoli .(28,49) 
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HIGH GRADE PIN (HGPIN): Characterized by cellular 
proliferation within medium to large glands characterized additionally by 
cytologic atypia. Regardless of the architectural pattern, nuclear changes are 
the hall mark of high grade PIN. Nuclei are enlarged with hyperchromasia 
and irregular chromatin. Nucleoli are large, irregular,often multiple and may 
be focal(Grade 2PIN) or  more extensive(Grade 3 PIN). (28,49,55) 
HISTOLOGIC SUBTYPES OF  PIN: (28,49) 
1) Tufted 
2) Micropapillary 
3) Cribriform 
4) Flat 
5) Others: 
- Epithelial arches 
- Trabecular bars 
- Roman bridges 
- Solid patterns. 
The basal cell-specific, high molecular weight keratin demonstrates a 
complete absence or discontinuous layer, a feature important in the 
differential diagnosis with prostatic carcinoma. (4,13) 
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CLINICAL SIGNIFICANCE OF PIN 
The finding of low-grade PIN should not prompt further investigation 
and it is not reproducibly recognized. In contrast, high grade PIN is an 
important diagnosis, but should be made with care. If high-grade PIN is 
encountered in a needle biopsy specimen, additional levels should be 
considered to rule out carcinoma. A diagnosis of high-grade PIN without 
concurrent carcinoma should prompt careful clinical follow-up and further 
biopsies, especially if the serum PSA is elevated or abnormalities are noted 
on rectal or ultrasound examination. (7,10,18, 41) 
ATYPICAL ADENOMATOUS HYPERPLASIA (ADENOSIS) 
AAH is characterized by proliferating small to medium-sized acini 
that usually form a well-circumscribed nodule but occasionally extend in to 
the adjacent prostatic stroma. This has been identified in 1.5 to 19.6% of 
transurethral resectates and in up to 33% of radical prostatectomies. (8, 12, 32) 
The evidence associating AAH and carcinoma is mainly 
circumstantial. The age of patient with AAH in usually 5-10 years less than 
that of carcinoma. AAH reportedly occurs more commonly in glands 
harboring cancer than in benign ones. Since AAH is often seen in transition 
zone, it has been suggested that it may be related to adenocarcinoma 
developing at this site. (28, 49, 55) 
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The basal cell-specific HMWK usually shows a discontinuous pattern. 
Basophilic mucin is rare, but when present is positive with the alcian blue 
stain. (4, 13) 
From a therapeutic perspective, AAH is considered benign and 
patients should be followed conservatively. (12) 
CARCINOMA OF THE PROSTATE 
Establishing, or ruling out, the diagnosis of carcinoma of the prostate 
has been a well-known challenge for pathologists for many years. In the 
western countries, prostatic adenocarcinoma is the most common 
noncutaneous malignant neoplasm in humans, and is second only to lung 
cancer in mortality. Both incidence and mortality rate have increased over 
the last few decades all over the world, even in India. (11, 19, 28) 
Clinically manifest prostatic cancer usually occurs in the sixth to 
eighth decades and is uncommon in patients under 50 years of age. There is 
considerable geographic variation  in the incidence and mortality rates for 
prostatic cancer. Low rates are seen in the far east and very high  rate in 
Northern European and North American populations. (19, 28, 49) 
The etiology and pathogenesis of prostate cancer are poorly 
understood. Both genetic and epigenetic factors have been implicated. There 
is a well-documented familial association in a minority of cases. The 
strongest risk factors are advancing age, race, heredity and hormonal 
activity. The other doubtful factors are viruses, cadmium exposure, high fat 
diet, vitamin A and D deficiency etc. (41, 49, 55, 59) 
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CLINICAL FEATURES: 
Most often asymptomatic, but locally extensive tumours cause pubic 
pain, rectal obstruction or bleeding. Presenting symptoms of metastatic 
disease include bone pain and tenderness, cord compression. Occasionally, 
enlarged lymphnodes may be the presenting symptoms. On rare occasions, 
prostatic carcinoma may manifest as a paraneoplastic syndrome. (8, 11, 12, 55) 
Screerning methods for prostatic carcinoma are Digital rectal 
examination (DRE), measurement of serum PSA, transrectal ultra sound 
(TRUS). The detection rate for DRE is about 0.8-2.7%. But, most 
carcinomas detected by transurethral resection and in PSA screening  
programs are not palpable. (49, 55, 59) 
In many patients, abnormal PSA elevation may be the first finding. A 
PSA value above 4 ng/ml  is considered abnormal. 4-10 ng/ml -low range 
abnormality>10ng/ml- High range abnormality .A variety of PSA indices 
have been developed, including age-specific PSA tables, PSA density, PSA 
velocity. (8, 11, 59) 
On TRUS, areas of hypoechogenicity may be detected. But in some 
cases no abnormalities are seen. Directed biopsies of abnormal areas can be 
obtained, and if no abnormalities are detected, multiple areas are 
systematically biopsied. Commonly a sextant approach is undertaken 
,biopsies form the basal, mid and apical portions of the gland, with or 
without the transition zone, are taken on both sides. (12, 19, 21, 49) 
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PATHOLOGIC FEATURES: 
The goal of the pathologic examination is to provide the necessary 
information to guide further therapy and assess the prognosis. Prostatic 
carcinomas can be divided in to two major categories:  
1) Adenocarcinoma of peripheral ducts and acini. 
2) Carcinoma of large ducts.  
Recently, it is proposed that, it is the site of the growth, rather than the 
origin that governs the tumour architecture. (8, 11, 19) 
 Most prostatic carcinomas arise in the peripheral zone. Grossly the 
tumour may be difficult to see but usually can be identified as gray or 
yellowish, poorly delineated, firm area.Microscopically,prostatic 
adenocarcinomas exhibit a wide spectrum of appearances, ranging from 
anaplastic tumours to highly differentiated neoplasms which will be very 
difficult to differentiate from normal and benign glands. (11, 21, 32) 
The accurate diagnosis of prostatic adenocarcinoma involves 
familiarity with the protean patterns and identification, in most cases, of 
features indicative of invasion and also abnormal cellular features, especially 
those related to the nucleus. Supportive cytoplasmic and luminal features 
also play a role. (28, 49, 55) 
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GLEASON’S GRADING SYSTEM (11, 19, 21, 25, 28, 32, 47, 49, 53, 55, 59) 
FIGURE 2 
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This is the most powerful prognostic indicator of prostate 
carcinoma. 
1. Single, Separate, uniform glands loosely packed, with definite edges. 
2. Single, separate, uniform glands loosely packed, with irregular edges. 
3A. Single, Separate, uniform glands, scattered. 
3B. Single, separate, very small glands, scattered. 
4A. Fused glands, raggedly infiltrating. 
4B. Same, with large pale cells (hypernephroid) 
5A. Almost solid, rounded masses, necrosis (“Comedocarcinoma”) 
5B. Anaplastic, raggedly infiltrating. 
STOUT CRITERIA FOR PROSTATIC ADENOCARCINOMA 
DIAGNOSIS (11, 53, 55) 
1. Glandular pattern-small irregular glands without any particular 
relation to the adjacent stroma or normal glands. 
2. Arrangement of glandular epithelium-lack of basal cells in cancer. 
3. Cellular details-large, deeply staining prominent nucleoli. 
criteria for diagnosis of prostatic adenocarcinoma. (11, 19, 28, 53, 55) 
Major criteria: 
Architectural: Infiltrative small glands or cribriform glands . 
Single cell layer (absence of basal cells) 
Nuclear atypia: Nuclear and nucleolar enlargement. 
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Minor criteria 
¾ Intraluminal wispy blue mucin 
¾ Pink amorphous secretions 
¾ Mitotic figures 
¾ Intraluminal crystalloids 
¾ Adjacent high grade PIN 
¾ Amphophilic cytoplasm 
Specific features of carcinoma 
1) Perinerual invasion 
2) Collagenous micronodules 
3) Glomerulations 
PROGNOSTIC FACTORS (49) 
 Category I - Serum  PSA 
    Gleason grade 
    Pathologic stage 
    Surgical margins 
 Category II - DNA ploidy 
    Volume of cancer in radical prostatectomy 
    Volume of cancer in needle biopsies 
    Histologic subtype 
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 Category III -Perineural invasion 
    Lymphnode micrometastases 
    Nuclear roundness 
    Nuclear chromatin texture 
    Mitotic figures 
    MIB-1 
    PCNA 
    Apoptosis 
    PSA derivatives 
    Androgen receptors 
TRANSITIONAL CELL CARCINOMA OF THE PROSTATE: 
Most pathologists and urologists have faced the problem of deciding 
whether a neoplasm is of prostatic or bladder origin. Primary neoplasm of 
either organ can invade the other. (8, 11 12, 19) 
Ende et al postulated that this neoplasm began in the periurethral and 
prostatic ducts  in the area of junction of columnar and transitional 
epithelium. (11, 19, 25, 28) 
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Karpas and Moumgius subsequently demonstrated that the 
hyperplastic transitional cells arise form the reserve cells lying  between 
luminal epithelium and basement membrane in the periurethral ducts. (11, 28, 
49) 
Johnson et al have atributed one of the three pathophysiological 
processes for the oncogenesis of transitional cell carcinoma of the prostate; 
1) Direct extension from a contiguous infiltrating vesical or prostatic 
urethral malignant lesions. 
2) Prostatic urethral implantation from an epithelial tumour 
elsewhere. 
3) Carcinogenic stimulation of periprostatic glandular urothelium 
resulting in neoplastic changes in the epithelium which may 
proceed to an infiltrating  prostate lesion. (28,49,55) 
PROLIFERATIVE STATUS 
Mitotic figures are rarely found in tissue sections in normal or 
hyperplastic prostatic epithelium.The number of mitotic figures increased 
progressively from benign epithelium through PIN to cancer. 
Adenocarcinomas with cribrifrom growth patterns and those composed of 
solid areas of undifferentiated tumour cells contained most mitotic figures. 
Therefore, proliferative cell nuclear antigen (PCNA) and Ki-67  antigens are 
used to assess miitotic activity. (4, 11, 13) 
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The number of mitotic figures correlated with cancer stage and grade 
as well as with the progression and progression free survival. Androgen 
deprivation therapy results in a dramatic  decline in the number of  mitotic 
figures in cancer. (4, 13, 19, 34) 
In prostate cancer, a high proliferation index for ki-67 appear to add 
predictive information for patient outcome above the traditional indicators of 
Gleason score, pathologic stage and DNA ploidy. However ki-67 labelling 
index may discriminate between organ corfined and metastatic cancer. 
Hence, elevation in the proliferation indices of Ki-67,MIB-1 appears to 
reflect progression. In combination , these findings suggest that ki-67 
expression may be one of the predictors of  recurrence, progression and 
survival. (4, 7, 11, 13, 28, 56) 
In post-radiation reccurence prostatic adenocarcinoma, the sole 
proliferation index by Ki-67 reached independent significance. 
Diagnostically this may become an important diagnostic factor as the 
number of patients surviving long-term following radical radiotherapy 
increases. (4, 28) 
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OBSERVATION AND RESULTS 
This prospective study included 120 cases of prostatic lesions which 
included Benign Nodular Hyperplasia,Prostatic abscess,precancerous lesions 
and frankly malignant lesions of varying grades.The clinical data including 
age of the patients,presenting symptoms,clinical diagnosis and 
histopathological data  are listed in the master chart. 
Incidence: 
 The incidence of prostatic lesions in this study is 1.8% (120 cases) of 
the total number of general biopsy specimen.This accounted for 87.5% of  
total urology specimen received during the period of  2006-2008. 
TABLE : 1 
Period Prostate biopsies Total Urology  
specimen 
June ’06-Dec’06 26 cases 30 
June ’07-May’07 32 cases 36 
June ’07-Dec’07 43 cases 49 
June ’08-May’08 19 cases 22 
Total 120 cases 137 
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            This clearly shows the number of patients presenting with prostatic 
symptoms in the urology clinic and the considerable morbidity  due to 
prostatic  diseases. 
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Age incidence: 
The distribution of cases according to age is shown in the graph.Out 
of 120 cases studied,maximum number of cases of both Nodular Hyperplasia 
and malignancy were seen in the seventh decade-49% 
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Distribution of prostatic lesions: 
 The following bar diagram shows the incidence of different prostatic 
lesions.Benign nodular hyperplasia is by far the most common type of 
lesion-90.8% (109 cases) followed by carcinoma 6.6 % (8 cases) and 
inflammatory lesions-1.7% (2 cases). 
FIGURE : 5 
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BENIGN NODULAR HYPERPLASIA 
 Out of all the prostatic lesions studied, Nodular hyperplasia 
constituted the bulk of the lesions (90.8%). 
 The following table shows the distribution of cases of nodular 
hyperplasia according to the age. The youngest patient reported in this study 
was 41 years and oldest patient was 83 years old.A progressive increase is 
observed in the incidence until the 7th decade. 
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TABLE 2 
Age Number of cases Percentage 
5th decade 5 45% 
6th decade 29 25.9% 
7th decade 53 47.3% 
8th decade 18 16.1% 
9th decade 6 5.4% 
 
Clinical grading of Nodular Hyperplasia: 
 The distribution of various degrees of enlargement of the prostate in 
different age group was studied..In this study, the patients presented with 
grade II and III only and no single case was noted with I/IV. Grade II –100 
Cases, Grade III-9 cases.Similar results were documented by the earlier 
work carried out by Hunt et al in which 8.7% of cases presented with grade I 
enlargement and 48% of cases with grade II enlargement.Grade III to IV 
enlargement of the prostate was observed in 33.9% and 7.8% of cases 
respectively. There was no significant correlation between the degree of 
enlargement of prostate and the morphological type of nodule. 
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Morphological types of nodules: 
 The incidence of 5 types of nodules is shown in the following pie 
chart. Fibromyoadenomatous nodule was the most common type  
encountered (55.1% - 60 cases) followed by fibroadenomatous nodules 
(21.1%-23 cases). The fibromuscular and muscular nodules constituted 
12.8% - 14 cases and 8.2% - 9 cases respectively. The least common type of 
nodule observed in this study was stromal nodule (2.8% - 3 cases). 
FIGURE : 6 
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Status of basal cells in Nodular Hyperplasia: 
All the sections of nodular hyperplasia were screened for the evidence 
of basal call hyperplasia, Nodular aggregates of basal cells were identified in 
42 cases (35%) in that 8 cases had complete basal cell hyperplasia. In 26 
cases (23.2%) basal cell hyperplasia was associated with atrophic changes in 
the acini. 
Prostatic intraepithelial Neoplasia (PIN): 
All the sections of Nodular Hyperplasia were carefully scrutinized for 
the evidence of PIN and graded when present. Low grade PIN was noted in 
33 cases-27.5% and high grade PIN in 3 cases-25% . 
Other associated findings: 
In 51 cases (42.5%) focal or diffuse lymphocytic infiltration was 
present. 5.8% cases (7cases) showed squamous metaplasia and 6.7% (8 
cases) showed transitional metaplasia of the acini. Corpora amylacea was 
noted in 76.8% (86 Cases). 
Many cases showed cystic dilatation and flattening of the lining cells 
atleast focally. 
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MALIGNANT LESIONS OF THE PROSTATE 
Incidence: 
In our prospective study, malignant lesions constituted the second 
most common pathology of prostate.  
This study includes a total of 8 cases  (6.6%) of malignant lesions of 
the prostate. 
We also observed that carcinoma of prostate was the third common 
malignancy of the male genital tract next only to carcinoma of penis and 
bladder.Prostatic carcinoma was closely followed by  malignancy of testis 
and urethra, which is shown in the following bar diagram. 
FIGURE : 7 
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Age incidence: 
The age at diagnosis of prostatic carcinoma reported in this study 
ranged form 51 to 70  years with average age of 61 years.The age distribution 
is as follows 
¾ 50-59 year 2 cases 25% 
¾ 60-69 year 5 cases 62.5% 
¾ 70-79 year 1 case  12.5% 
Maximum number of cases were seen in the 7th decade. 
Histologic distribution of malignant lesions: 
8 cases of malignancies of the prostate were studied. Adenocarcinoma 
was the most common (7 cases-87.5%) type of primary carcinoma 
encountered. 1 case (12.5%) of transitional cell carcinoma of prostate was 
noted. 
Grading of adenocarcinoma of the prostate: 
 Gleason’s grading system of adenocarcinoma cases is shown in the 
following table.Based on Gleason’s criteria, 7 cases of adenocarcinoma were 
reviewed and assigned to the specific category according to the five 
histological patterns. 
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In the Gleason’s, tertiary grading system,among the five patterns 
described the predominant pattern present in the biopsy was noted and 
assigned the first number.The second common and the least common 
patterns were noted and assigned the second and third numbers 
respectively.Finally all these three numbers were added together and the 
Gleason’s score thus obtained. 
GLEASON’S TERTIARY GRADING SYSTEM FOR CARCINOMA:  
TABLE : 3 
S.No PATH NO 
HPE 
DIAGNOSIS 
GLEASON’S 
GRADE 
GLEASON’S 
SCORE 
1.  3034/06 Adenocarcinoma 2+3+1 6 
2.    266/07 Adenocarcinoma 4+5+3 12 
3.  1484/07 Adenocarcinoma 5+3+4 12 
4.  2350/07 Adenocarcinoma 3+2+1 6 
5.  2644/07 Adenocarcinoma 2+3+1 6 
6.  1030/08 Adenocarcinoma 2+3+1 6 
7.  1092/08 Adenocarcinoma 4+3+2 9 
 
This shows the presence of higher grades(3,4,5) as the predominant 
pattern in the majority of the cases which will clearly affect the prognosis. 
Prostatic intraepthelial neoplasia: 
Foci of high grade intraepithelial neoplasia was noted in all the 7 
cases (100%) of adenocarcinoma. 
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Perineural invasion: 
Only one case (12.5%) showed the evidence of perineural invasion in 
the present study whereas a study by Rodis et al reported an incidence of 
41.6%.It seems likely that perineural invasion would have been 
demonstrated in additional cases, if radical prostatectomy specimen and 
complete serial sections would have been possible. 
Mucin histochemistry in prostatic lesions: 
 15 cases were selected for PAS and alcian blue staining, including 7 
cases of frank adenocarcinoma, 1 case of transitional cell carcinoma, 2 cases 
of high grade PIN, 2 cases of low grade PIN, 1case of atypical adenomatous 
hyperplasia and  2 cases of Nodular Hyperplasia. 
Type of stain  Purpose    Result 
PAS   Stains neutral mucins  Glycogen and related  
   and glycogen    mucin-Pink 
Alcian blue  Stains all acid mucins  Total acid mucin -Blue 
at PH 2.5   
The following table shows the results of mucin histochemistry. 
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MUCIN HISTOCHEMISTRY TABLE:  
TABLE : 4 
S.No PATH NO HPE DIAGNOSIS ALCIAN BLUE PAS 
1. 342/08 Nodular Hyperplasia Negative  Positive 
2. 560/08 Nodular Hyperplasia Negative Positive 
3. 3399/07 AtypicalAdenomatousHyperplasia Positive  Negative
4. 222/08 Nodular Hyperplasia, LGPIN Negative Positive 
5. 223/08 Nodular Hyperplasia, LGPIN Negative Positive 
6. 2863/06 Nodular Hyperplasia, HGPIN Negative Positive 
7. 267/08 Nodular Hyperplasia,HGPIN Positive Negative
8. 3034/06 Adenocarcinoma Negative Positive 
9. 266/07 Adenocarcinoma Positive Negative
10. 1484/07 Adenocarcinoma Positive Negative
11. 2350/07 Adenocarcinoma Positive Positive 
12. 2600/07 Adenocarcinoma Negative Positive 
13. 1030/08 Adenocarcinoma Negative Positive 
14. 1092/08 Adenocarcinoma Positive Negative
15. 3411/07 Transitional Cell Carcinoma  Negative Negative
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Results: 
¾ In 4 cases (57.1%) of adenocarcinoma, intraluminal blue 
stained acidic mucin could be demonstrated. 
¾ All cases of Nodular Hyperplasia and LGPIN were devoid of 
acidic mucin. 
¾ 1 out of 2 cases of HGPIN showed the presence of acid mucin. 
¾ 1 case of AAH showed positivity for acidic mucin. The 
intensity of staining was similar in both carcinoma and AAH. 
These findings indicate that there is a close relation in mucin 
expression between AAH and well differentiated 
adenocarcinoma. 
The incidence of acidic mucin was not only higher in prostatic 
carcinomas but also directly proportional to the tumour grade in all but the 
poorly differentiated ones.. 
Transitional cell carcinoma was negative for both acidic and neutral 
mucin. 
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Immunohistochemistry with Ki-67: 
10 cases were selected to study the status of proliferative activity 
which included 2 cases of nodular hyperplasia, 2 cases of LGPIN, 2 cases of 
HGPIN and 4 cases of carcinoma of varying grades. 
The following table shows the Ki-67 Labelling Index (Ki-67 
LI)obtained in each case; 
TABLE :5 
S.No    Path no HPE Diagnosis Ki-67 LI 
1 266/08 Nodular Hyperplasia    0 
2 562/08 Nodular Hyperplasia    1  
3 3108/06 LGPIN    1 
4 2567/07 LGPIN    2 
5 2863/06 HGPIN    3 
6 267/08 HGPIN    3 
7 3034/06 Low Grade Ca    9 
8 2644/07 Low Grade Ca   10 
9 2350/07 High Grade Ca   10 
10 1484/07 High Grade Ca   27 
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Results: 
¾ Both cases of Nodular Hyperplasia showed less than 1% positive 
staining. One case of low grade PIN should 1% and the other showed 
2% as Ki-67 labelling index. 
¾ Both the two cases of high grade PIN showed 3% as ki-67 labelling 
index. 
¾ Among carcinoma, one case with Gleason’s score of 6 showed 9% Ki-
67 LI, other with score 6 showed 10% Ki-67 LI. Two higher grade 
carcinomas with scores 9 and 12 had 12% and 27% as their Ki-67  LI  
respectively. 
 Thus, the proilferative status increased progressively from benign 
epithelium through PIN to cancer. Even in carcinoma higher grade 
carcinomas had higher labelling index than lower grade carcinomas. 
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DISCUSSION 
Prostate hosts a number of diseases ranging from inflammation to 
carcinoma.This leads to considerable morbidity and mortality worldwide. 
Among the diseases of prostate, benign nodular hyperplasia is the most 
commonly observed pathology. In our Prospective study, the distribution of 
prostatic lesions is shown in the following pie chart. 
FIGURE : 8 
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BENIGN NODULAR HYPERPLASIA 
The development of nodular hyperplasia is age related.(11,19,20) In our 
study,the youngest patient was 40 years old and the oldest patient was 82 years 
old.Many pathologists have proved that testosterone is a powerful stimulation for 
the development of hyperplasia. This is also supported by the regression of the 
nodules after androgen deprivation (32,47,48,49) 
The principal androgenic hormones are testosterone and dihydrotestosterone 
(DHT).The DHT level is elevated in tissues with nodular hyperplasia compared to 
normal tissue in some studies There is no clear relationship between plasma DHT 
levels and the clinical presence of nodular hyperplasia (41,47,48,49) 
Current experimental work is looking at the exact roles of hormone growth 
factors and their respective receptors.  
There is also considerable interest in the role of programmed cell death in 
the development of nodular hyperplasia.(28,32,44) 
In our prospective study,the highest incidence of nodular hyperplasia was 
noted in the 7th decade. The number of cases in each decade in shown in the 
following graph . 
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Age incidence of nodular hyperplasia-A comparative analysis. 
TABLE : 6 
S.No STUDY 
TOTAL 
NO OF 
CASES 
40-49 
Yrs,% 
50-59 
Yrs,% 
60-69 
Yrs,% 
70-79 
Yrs,% >80 Yrs,% 
1. YOUNG 450 14, 
3.1% 
79, 
17.6% 
199, 
44.2% 
146, 
34.4% 
12, 2.7% 
2. HUNT 1000 16, 
1.6% 
258, 
25.8% 
564, 
50.4% 
155, 
15.5% 
7, 7. 7% 
3. KARLE 
BEECHAAM 
60 6, 10% 14, 
23.3% 
30, 
50% 
9, 15% 1, 1. 7% 
4. KRETSCHMER 651 13, 2% 130, 
19.9% 
311, 
47.7% 
166, 
25.5% 
31, 4.8% 
5. PRESENT 
STUDY 
112 5, 4.5% 29, 
25.9% 
53, 
47.3% 
18, 
16.1% 
6, 5.4% 
 
The incidence of nodular hyperplasia in each decade observed in our study is 
comparable with other similar studies. 
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The actual incidence of Nodular Hyperplasia should be more in 8th and 9th 
decades.But, due to age related deaths, the incidence in spuriously lesser. 
Regarding morphological subtype of benign nodular hyperplasia , Frank 
classified it in to 5 types and our study states that fibromyoglandular is the 
commonest subtype observed. 
Basal cell hyperplasia 
Since basal cell hyperplasia is usually seen in cases of nodular hyperplasia, 
the clinical features are essentially the same as those of that condition.The only 
different significant clinical association is with anti androgen therapy. Basal cell 
hyperplasia is typically found in the transition zone and is therefore usually 
identified in the transurethral resection.This may also be atrophy associated and 
found in the peripheral zone. (11,28,32,55) 
 In our study,42 cases of nodular hyperplasia were associated with basal cell 
hyperplasia.In them,8 cases had complete basal cell hyperplasia.In 26 cases of 
nodular hyperplasia, basal cell hyperplasia was associated with atrophic changes in 
the acini.This correlates well with previous studies by Young and Frankel et al. 
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PIN : 
Prostatic intraepithelial neoplasia is best characterized as a neoplastic 
transformation of the 1ining epithelium of prostatic ducts and acini. By 
definition,this process is confined to within the epithelium, therefore 
intraepithelial.(45,53) 
There is limited literature characterizing the epidemiology of high grade 
prostatic intraepithelial neoplasia. Based on few recent autopsy studies that 
included HGPIN in their analysis, it appears that similar to prostate cancer, HGPIN 
can be detected microscopically in young males, its prevalence increased with age 
and HGPIN shows strong association with cancer in terms of coincidence in the 
same gland and its spatial distribution.(45,48,49)  
Sakr et al. identified HGPIN in 7,26,46,72,75 and 91% of African-
Americans between the third and eighth decades compared to 8,23,29,49,53, and 
67% for caucasian men.(59) The incidence of HGPIN in transurethral resection of 
the prostate is relatively uncommon with two studies reporting a rate of 2.3 and 2.8 
% respectively.(28) 
Our study correlates well with this, stating 2.5% prevalence of HGPIN in 
TURP specimen. 
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The prevalence of high grade PIN in radical prostatectomy or TURP for 
carcinoma is remarkably high reflecting the strong association with malignancy. 
Investigators have found HGPIN in 85-100% of radical prostatectomy 
specimen.(28) 
Our study included 7 cases of prostatic adenocarcinoma, which were all 
TURP specimen.All cases exhibited atleast focal areas of HGPIN. 
We also observed that the association of LGPIN with nodular hyperplasia 
was 27.5%  
There are many evidences to suggest morphological relationship of HGPIN 
and prostatic adenocarcinoma: 
¾ The incidence and extent of both lesions increase with patient age. 
¾ There is an increased frequency,severity and extent of HGPIN in 
prostatic carcinoma. 
¾ Both HGPIN and carcinoma are multifocal with a predominant 
peripheral zone distribution. 
¾ Histological transition from HGPIN to cancer has been described. 
¾ HGPIN is more strongly associated with intermediate and high grade 
prostatic carcinoma. 
¾ There is significant correlation between volume of HGPIN and the 
number of lymphnode metastases. (28,49,55,59) 
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Risk of subsequent cancer detection after rebiopsy (28) 
Needle biopsy diagnosis % of carcinoma on rebiopsy 
¾ Benign prostatic tissue 20% 
¾ 2) High grade PIN 30% 
¾ 3) PIN with small atypical glands 53% 
Prostatic adenocarcinoma: 
Prostatic cancer contributes significantly to the over all cancer burden, being 
the most frequent malignancy in men,worldwide.The number of cases had 
continuosly increased over the past decades,partly due to the higher life 
expectancy.An additional factor is the western lifestyle characterized by a high 
caloric diet and lack of physical exercise.Epidemiological data suggest that black 
people are most susceptible,followed by white people,while the Asians have the 
lowest risk.(28,32,41,47,53,55) 
Histopathological diagnosis and grading play a major role in the 
management of prostate cancer.(28,47,53) 
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PROSTATE CANCER INCIDENCE:ASR/10 
FIGURE : 10 
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International trends in age standardized mortality rates of prostate 
caner(World Standard) source:WHO/NCHS 
FIGURE : 11 
 
 
The risk of prostate cancer rises very steeply with age.Incidence of clinical 
disease is low until after age 50,and then increases at approximately the 9-10 th 
power of age,compared with the 5-6 th power for other epithelial 
cancers.Worldwide,about three-quarters of all cases occur in men aged 65 or 
more.(28,47,53) 
Our study includes 8 cases of prostatic carcinomas which account for 5.8% 
of total urology specimen and 6.6% of prostatic biopsies.The age of the patients 
ranged from 51-70 years with an average of 61 years. 
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The distribution of cases according to the age is shown below:  
50-59 year  2 cases  25% 
60-69 year  5 cases  62.5% 
70-79 year  1 case  12% 
The youngest patient was 51 years old and the oldest patient was 70 
years old. 
 
Features helpful in the diagnosis of adenocarcinoma in needle biopsy 
specimen (49) 
1) Infiltrative pattern 
2) Nuclear enlargement 
3) Prominent nucleoli 
4) Pink amorphous secretions 
5) Amphophilic cytoplasm 
6) Blue tinged mucinous secretions 
7) Nuclear hyperchromasia 
8) Intraluminal crystalloids 
9) Mitotic figures 
10) High grade PIN 
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Features specific for malignancy: 
¾ Glomerulations 
¾ Mucinous fibroplasia 
¾ Perineural invasion 
In our study, the features commonly noted were infiltrative pattern,nuclear 
enlargement,prominent nucleoli,adjacent HGPIN,amphophilic cytoplasm and 
mitotic figures. 
All cases were associated with adjacent HGPIN in our study and in one case we 
noted perineural invasion which is a special feature of prostatic carcinoma.We 
have not observed glomerulations or collagenous micronodules. 
 
GLEASON’S GRADING SYSTEM: 
This is the most powerful prognostic indicator of prostatic 
adenocarcinoma.(19,28,53,55) We applied Gleason’s tertiary grading system for all 
adenocarcinomas and the following table shows the Gleason’s grade and score of 
the 7 carcinomas  
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GLEASON’S TERTIARY GRADING SYSTEM FOR CARCINOMA:  
TABLE : 7 
S.No PATH NO HPE DIAGNOSIS GLEASON’S GRADE GLEASON’S SCORE 
8. 3034/06 Adenocarcinoma 2+3+1 6 
9. 266/07 Adenocarcinoma 4+5+3 12 
10 1484/07 Adenocarcinoma 5+3+4 12 
11 2350/07 Adenocarcinoma 3+2+1 6 
12 2644/07 Adenocarcinoma 2+3+1 6 
13 1030/08 Adenocarcinoma 2+3+1 6 
14 1092/08 Adenocarcinoma 4+3+2 9 
 
The higher the grade,the less favourable is the prognosis and this is clearly 
shown in the following figure. 
FIGURE : 12 
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Ki-67 LABELLING INDEX (Ki -67 LI) : 
Many recent literature clearly document the importance of proliferative 
markers in assessing the prognosis of prostatic carcinoma.(4,13,33) 
The mitotic activity gradually increased form benign epithelium through PIN 
to malignancy. We observed the same in our study with ki-67 marker.We selected 
10 cases which included Nodular hyperplasia,LGPIN, HGPIN, low grade and high 
grade carcinomas. The results are plotted in the graph taking the average of each of 
the two similar cases,and the graph goes fairly well with the literature. 
FIGURE : 13 
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Metastasis: 
Prostatic carcinoma is well known for its local spread and distant metastases. 
The common sites of local spread are periprostatic tissues,seminal vesicle,urethra 
and bladder. The most common sites of prostate cancer metastases is shown in the 
following figure.(28,47,53,55) 
THE TEN MOST COMMON SITES OF PROSTATE CANCER METASTASES 
AT AUTOPSY IN THE UNITED STATES AND JAPAN 
FIGURE : 14 
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In our study, we lost the patients for follow up and therefore we could not 
get the incidence and common sites of metastases. 
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CONCLUSION 
In the present prospective study comprising of 120 cases of prostatic lesions 
evaluated with clinical,light microscopy,histochemical and IHC, following 
conclusions are made and presented. 
1) Benign Nodular Hyperplasia is the most commonly observed pathology of 
prostate. 
2) The age incidence of Nodular Hyperplasia is between 5 th and 7 th decade. 
3) Fibromyoadenomatous nodule is the most frequently encountered type of 
Nodular Hyperplasia. 
4) The incidence of Low Grade Prostatic Intraepithelial Neoplasia is 27.5% 
and High Grade Prostatic Intraepithelial Neoplasia is 2.5 % in TURP 
specimen of Nodular Hyperplasia. 
5) Among the primary malignant neoplasms of the prostate,Adenocarcinoma 
is the commonest. 
6) All cases of Adenocarcinoma showed atleast focal presence of adjacent 
High Grade Prostatic Intraepithelial Neoplasia. 
7) Higher grades, according to Gleason’s Grading system are more 
commonly observed as the predominant pattern,rather than lower grades. 
 
8) Normal and hyperplastic glands exhibited the presence of neutral mucin 
whereas,High Grade Prostatic Intraepithelial Neoplasia,Atypical 
Adenomatous Hyperplasia and carcinomas showed predominance of 
acidic mucin. 
9) Mitotic activity progressively increased from benign epithelium through 
Prostatic Intrraepithelial Neoplasia to malignancy. 
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10) Even among malignant lesions,those with higher Gleason’s grade and 
scores had higher Ki-67 labelling index than those with lower Gleason’s 
grade and score.  
KI-67 LABELLING INDEX which was widely used in various other 
neoplasms,has now gained importance as an indicator of cell proliferation in 
prostatic carcinoma.In normal and benign epithelium,mitotic activity is 
indiscernible.In rapidly proliferating epithelium such as in precursor lesions 
and prostatic carcinoma, mitotic activity increases steadily and it can be 
readily shown by Ki-67 Labelling Index. 
So,ASSESSING THE MITOTIC ACTIVITY WITH A PROLIFERATIVE 
MARKER SUCH AS KI-67 IS A REPRODUCIBLE, SIMPLE,EFFICIENT, 
RELIABLE  AND  RELATIVELY  INEXPENSIVE METHOD AND CAN BE USED 
AS AN ADJUNCT TO ROUTINE DIAGNOSIS OF PROSTATIC CARCINOMA 
ESPECIALLY IN DOUBTFUL CASES AND ALSO IN ASSESSING THE 
PROGNOSIS.  
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MASTER CHART 
S.NO:  PATH NO AGE CLINICAL DIAGNOSIS  HPE DIAGNOSIS 
1 1719/06 45 BPH – GRADE II NODULAR HYPERPLASIA 
2 1758/06 50 BPH – GRADE II NODULAR HYPERPLASIA 
3 1759/06 68 BPH – GRADE II NODULAR HYPERPLASIA 
4 1820/06 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
5 1821/06 72 BPH – GRADE II NODULAR HYPERPLASIA 
6 1852/06 56 BPH – GRADE II NODULAR HYPERPLASIA 
7 2107/06 70 BPH – GRADE II NODULAR HYPERPLASIA 
8 2124/06 60 BPH – GRADE II NODULAR HYPERPLASIA 
9 2125/06 58 BPH – GRADE II NODULAR HYPERPLASIA 
10 2623/06 75 BPH – GRADE II NODULAR HYPERPLASIA 
11 2863/06 64 BPH – GRADE II NODULAR HYPERPLASIA,HGPIN 
12 3034/06 60 BPH – GRADE II ADENOCARCINOMA 
13 3038/06 70 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
14 3086/06 80 BPH – GRADE II NODULAR HYPERPLASIA 
15 3163/06 63 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
16 3241/06 60 BPH – GRADE II NODULAR HYPERPLASIA 
17 3242/06 65 BPH – GRADE II NODULAR HYPERPLASIA 
18 3247/06 60 ? CARCINOMA CLUSTER OF DYSPLASTIC CELLS 
19 3290/06 75 BPH – GRADE III NODULAR HYPERPLASIA 
20 3292/06 60 BPH – GRADE II NODULAR HYPERPLASIA 
21 3312/06 50 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
22 3384/06 56 BPH – GRADE II NODULAR HYPERPLASIA 
23 3433/06 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
24 3444/06 62 BPH – GRADE II NODULAR HYPERPLASIA 
25 3496/06 70 BPH – GRADE II NODULAR HYPERPLASIA 
26 3497/06 55 BPH – GRADE II NODULAR HYPERPLASIA 
27 266/07 51 BPH – GRADE II ADENOCARCINOMA 
28 268/07 55 BPH – GRADE II NODULAR HYPERPLASIA 
29 339/07 63 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
30 340/07 55 BPH – GRADE II NODULAR HYPERPLASIA 
31 362/07 61 BPH – GRADE II NODULAR HYPERPLASIA,HGPIN 
32 443/07 65 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
33 531/07 40 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
34 892/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
35 933/07 70 BPH – GRADE II NODULAR HYPERPLASIA 
36 934/07 50 BPH – GRADE II NODULAR HYPERPLASIA 
37 960/07 55 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
38 1092/07 65 BPH – GRADE II NODULAR HYPERPLASIA 
39 1094/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
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40 1137/07 75 BPH – GRADE II NODULAR HYPERPLASIA 
41 1215/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
42 1250/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
43 1251/07 45 BPH – GRADE II NODULAR HYPERPLASIA 
44 1291/07 82 BPH – GRADE II NODULAR HYPERPLASIA 
45 1292/07 80 BPH – GRADE II NODULAR HYPERPLASIA 
46 1293/07 68 BPH – GRADE II NODULAR HYPERPLASIA 
47 1322/07 65 BPH – GRADE II NODULAR HYPERPLASIA 
48 1323/07 71 BPH – GRADE II NODULAR HYPERPLASIA 
49 1436/07 69 BPH – GRADE II NODULAR HYPERPLASIA 
50 1483/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
51 1484/07 65 BPH – GRADE II ADENOCARCINOMA 
52 1487/07 58 BPH – GRADE II NODULAR HYPERPLASIA 
53 1504/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
54 1505/07 68 BPH – GRADE II NODULAR HYPERPLASIA 
55 1630/07 62 BPH – GRADE II NODULAR HYPERPLASIA 
56 1631/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
57 1726/07 55 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
58 1860/07 64 BPH – GRADE II NODULAR HYPERPLASIA 
59 1867/07 60 BPH – GRADE III NODULAR HYPERPLASIA,HGPIN 
60 1944/07 83 BPH – GRADE II NODULAR HYPERPLASIA 
61 2031/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
62 2092/07 81 BPH – GRADE II NODULAR HYPERPLASIA 
63 2093/07 81 BPH – GRADE II NODULAR HYPERPLASIA 
64 2349/07 55 BPH – GRADE II NODULAR HYPERPLASIA 
65 2350/07 56 BPH – GRADE II ADENOCARCINOMA 
66 2389/07 56 BPH – GRADE II NODULAR HYPERPLASIA 
67 2440/07 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
68 2539/07 65 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
69 2567/07 58 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
70 2586/07 45 BPH – GRADE II NODULAR HYPERPLASIA 
71 2635/07 61 BPH – GRADE II NODULAR HYPERPLASIA 
72 2644/07 62 BPH – GRADE II ADENOCARCINOMA 
73 2645/07 51 BPH – GRADE II NODULAR HYPERPLASIA 
74 2646/07 62 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
75 2647/07 45 BPH – GRADE II NODULAR HYPERPLASIA 
76 2689/07 54 ABSCESS ABSCESS 
77 2694/07 57 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
78 2719/07 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
79 2802/07 57 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
80 2809/07 50 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
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81 2875/07 71 BPH – GRADE II NODULAR HYPERPLASIA 
82 2876/07 72 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
83 2982/07 72 BPH – GRADE II NODULAR HYPERPLASIA 
84 3003/07 55 BPH – GRADE II NODULAR HYPERPLASIA 
85 3012/07 62 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
86 3044/07 70 BPH – GRADE II NODULAR HYPERPLASIA 
87 3094/07 80 BPH – GRADE II NODULAR HYPERPLASIA 
88 3095/07 63 BPH – GRADE II NODULAR HYPERPLASIA 
89 3108/07 57 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
90 3109/07 65 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
91 3117/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
92 3162/07 70 BPH – GRADE II NODULAR HYPERPLASIA 
93 3216/07 61 BPH – GRADE II NODULAR HYPERPLASIA 
94 3217/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
95 3222/07 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
96 3378/07 56 BPH – GRADE II NODULAR HYPERPLASIA 
97 3399/07 75 BPH – GRADE II ATYPICAL ADENOMATOUS 
HYPERPLASIA 
98 3411/07 53 BPH – GRADE II TRANSITIONAL CELL CARCINOMA 
99 3413/07 60 BPH – GRADE II NODULAR HYPERPLASIA 
100 3429/07 72 BPH – GRADE II NODULAR HYPERPLASIA 
101 3430/07 55 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
102 6/08 60 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
103 67/08 65 BPH – GRADE II NODULAR HYPERPLASIA 
104 138/08 60 BPH – GRADE II NODULAR HYPERPLASIA 
105 151/08 63 BPH – GRADE II NODULAR HYPERPLASIA 
106 222/08 65 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
107 223/08 55 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
108 266/08 65 BPH – GRADE II NODULAR HYPERPLASIA 
109 267/08 70 BPH – GRADE II NODULAR HYPERPLASIA,HGPIN 
110 325/08 59 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
111 340/08 57 BPH – GRADE II NODULAR HYPERPLASIA 
112 341/08 75 BPH – GRADE II NODULAR HYPERPLASIA 
113 342/08 58 BPH – GRADE II NODULAR HYPERPLASIA 
114 560/08 60 BPH – GRADE II NODULAR HYPERPLASIA 
115 561/08 50 BPH – GRADE II NODULAR HYPERPLASIA,LGPIN 
116 562/08 60 BPH – GRADE II NODULAR HYPERPLASIA 
117 878/08 60 BPH – GRADE II NODULAR HYPERPLASIA 
118 939/08 60 BPH – GRADE II ABSCESS 
119 1030/08 70 BPH – GRADE II ADENOCARCINOMA 
120 1092/08 60 CA PROSTATE ADENOCARCINOMA 
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                           APPENDIX  
 
            I. HAEMATOXYLIN AND EOSIN 
Preparation of the solution: 
 
Distilled water                    - 1000 ml 
Ammonium alum               - 100 g 
Haematoxylin                     - 5 g 
Absolute Ethyl Alcohol      - 50 ml 
Mercuric Oxide                   - 2.5 g 
 
100 g of ammonium alum dissolved in 1000 ml of distilled water by heating and shaking at 
60oC.Add solution of 50 g of haematoxylin in 50 ml of ethyl alcohol and bring rapidly to 
boil.When it begins to boil,remove from flame and add 2.5 g of Mercuric oxide.Mix by swirling 
gently. 
 
                                         EOSIN STAIN 
 
Eosin Y                              - 1 g 
Distilled water                   - 20 ml 
95% Ethanol                      - 80 ml 
Glacial acetic acid             - 0.2ml 
 
Dissolve 1 g eosin Y in 20 ml of water and add  95% ethanol and glacial acetic acid. 
 
Procedure: 
 
1.  Sections to water 
 
 2. Alum Hematoxylin (Harris) 
 
 3. Quick rinse in  water 
 
 4. Dehydration- 1% acid alcohol- 3 to 4 times 
 
 5. Rinse in tap water-30 seconds 
 
 6. Stain 1 % aqueous eosin Y for ¼  to 2 minutes 
 
 7. Wash in water 
 
8. Clear and mount  
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II. PER-IODIC ACID SCHIFF STAINING 
 
Preparation of solution: 
 
   Coleman’s Feulgen reagent: 
             
        Basic Fuchsin                        -  1.0 gm 
        Potassium metasulphite        -  2.0 gm 
        Normal Hydrochloric acid    -  10 cc 
        Distilled water                       -  200 cc 
        Activated carbon                   -  0.5 gm 
 
Dissolve 1.0 gm Basic Fuschin in 200 cc of hot distilled water.Bring to boiling point.Cool and 
add 2.0 gm potassium metabisulphite and 10 cc normal hydrochloric acid.Let bleach for 24 hrs. 
 
Add 0.5 gm of activated carbon,shake 1 mt and filter until colourless, store in refrigerator. 
 
1% Per-iodic Acid solution:  
 
Per-iodic Acid crystals                 -  1 gm 
Distilled water                              -  100 cc 
 
Normal Hydrochloric Acid solution: 
 
Hydrochloric Acid Conc sp.Gr 1.19  -83.5 cc 
Distilled water                                    -916.5 cc 
 
 
Procedure: 
 
1. Smear fixed in methanol for 20 mts 
2. Air dried 
3. Per-iodic acid for 10 mts(oxidant) 
4. Rinse in distilled water 
5.Place in Coleman’s Feulgen reagent (Schiff’s reagent) for 30 mts 
6.Wash in tap water for 10 mts for pink colour to develop 
7. Immerse in hematoxylin for 1 to 2 mts 
8. Rinse in tap water 
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9. Differentiate in acid alcohol- 2 dips 
10. Wash in water 30 sec 
11.Two dips in ammonia water 2 % 
12. Wash in tap water- 30 sec 
13.Dehydrate in absolute alcohol 
14.Clear with xylene. 
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           III- ALCIAN BLUE STAINING 
 
Preparation of solution: 
 
Alcian Blue solution: 
 
 Alcian Blue                   - 8 gms 
 Distilled water               - 97 ml 
 Glacial Acetic Acid       - 3 ml 
 Thymol                          - 1 crystal 
 
 
Procedure: 
 
1. Sections hydrated in tap water. 
2. Placed in 3 % acetic acid for 2 minutes. 
3. Stained with Alcian blue solution for 30 minutes. 
4. Washed in running tap water for 2 minutes. 
5. Rinsed in distilled water. 
6. Dehydrated in absolute alcohol. 
7. Clearing done with Xylene.  
 
 
 
 
 
 
 
 74
 
 
 
 
                                          APPENDIX 
 
        IV - IMMUNO HISTOCHEMISTRY 
 
Procedure 
 
1. 5 microns thick sections were cut from the blocks received on slides coated with     
chrome alum gelatin. 
2. Slides were dewaxed and dehydrated in graded alcohol. 
3. Slides were immersed in 0.3 % Hydrogen peroxide for 20 minutes to block endogenous 
peroxidase activity. 
4. Washed in phosphate buffered saline (PBS) 
5. Incubated in primary antibody & Ki – 67. 
6. Washed in PBS. 
7. Biotinylated link was applied for 20 minutes. 
8. Washed in PBS. 
9. Incubated in streptavidin-biotin complex. 
10. Washed in PBS 
11. DAB was used as chromogen. 
12. Washed and  can be stained with haematoxylin. 
13. Mounted with coverslip. 
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